Summary

Infantile Spasms Therapeutics Market
The infantile spasms therapeutics market was valued at $162.0 million in 2023 and is projected to reach $223.4 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.
The infantile spasms therapeutics market focuses on the treatment of infantile spasms, which is a rare, severe form of epilepsy that occurs in infants between the age of 3 and 12 months. The primary treatment approaches comprise combinations of hormonal therapies, antiepileptic drugs (AEDs), and dietary interventions. Surgical interventions are considered during cases of intractable infantile spasms.

The growth of the infantile spasms therapeutics market is significantly driven by increase in awareness regarding the prevalence of neurological disorders and improvement in diagnostic capabilities. In addition, innovations in drug discovery and development have enhanced the potential of therapeutics, thereby augmenting the growth of the market. A prominent trend poised to dominate the market is the application of gene therapy & precision medicine to enhance the efficacy of treatment and improve patient outcomes. The incorporation of unique anatomical and genetic attributes of each patient via these ingenious methods is expected to reduce the occurrence of spasms in infants.

However, the high costs of therapeutics and potential side effects of different drugs deter several individuals from undergoing the treatment, restraining the growth of the infantile spasms therapeutics market. Moreover, challenges pertaining to diagnosis at early stages hamper the market growth notably. On the contrary, upsurge in funding & investments by governments or associated institutions is projected to fuel explorations in the field of infantile spasms therapeutics and present lucrative opportunities for the expansion of the market. For instance, CURE Epilepsy—an American non-profit research organization—awarded funds to Dr. David Auerbach at the Upstate Medical University in New York on December 2023 to investigate the role of cardiac biomarkers in epilepsy.

Segment Review
The infantile spasms therapeutics market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is divided into corticosteroids, adrenocorticotropic hormones (ACTH), antiepileptic drugs (AEDs), and others. Depending on route of administration, it is bifurcated into oral and parenteral. By distribution channel, it is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug type, the antiepileptic drugs (AEDs) segment is expected to dominate the market during the forecast period.
Depending on route of administration, the parenteral segment is projected to garner a high market share by 2033.
By distribution channel, the drug stores & retail pharmacies segment is anticipated to acquire a high share of the market throughout the forecast period.
Region wise, North America is predicted to be the highest revenue generator by 2033.
Competition Analysis
The major players in the global infantile spasms therapeutics market include Mallinckrodt Pharmaceuticals, H. Lundbeck A/S, Pfizer Inc., UCB Pharma S.A., Jazz Pharmaceuticals, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and AbbVie Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Drug Type
● Corticosteroids
● Adrenocorticotropic Hormones (ACTH)
● Antiepileptic Drugs (AEDs)
● Others
By Route Of Administration
● Oral
● Parenteral
By Distribution Channel
● Hospital Pharmacies
● Drug Stores and Retail Pharmacies
● Online Providers
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ France
○ Germany
○ Italy
○ Spain
○ UK
○ Rest of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ South Korea
○ Australia
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ South Africa
○ Saudi Arabia
○ Rest of LAMEA
● Key Market Players
○ Mallinckrodt Pharmaceuticals
○ H. Lundbeck A/S
○ Pfizer Inc.
○ UCB Pharma S.A.
○ Jazz Pharmaceuticals, Inc.
○ Novartis AG
○ Teva Pharmaceutical Industries Ltd.
○ Sun Pharmaceutical Industries Ltd.
○ Viatris Inc.
○ AbbVie Inc.

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Type
4.2. Corticosteroids
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Adrenocorticotropic Hormones (ACTH)
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Antiepileptic Drugs (AEDs)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Others
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Parenteral
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: INFANTILE SPASMS THERAPEUTICS MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Drug Type
7.2.3. Market Size and Forecast, By Route Of Administration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Infantile Spasms Therapeutics Market
7.2.6.1. Market Size and Forecast, By Drug Type
7.2.6.2. Market Size and Forecast, By Route Of Administration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Infantile Spasms Therapeutics Market
7.2.7.1. Market Size and Forecast, By Drug Type
7.2.7.2. Market Size and Forecast, By Route Of Administration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Infantile Spasms Therapeutics Market
7.2.8.1. Market Size and Forecast, By Drug Type
7.2.8.2. Market Size and Forecast, By Route Of Administration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Drug Type
7.3.3. Market Size and Forecast, By Route Of Administration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. France Infantile Spasms Therapeutics Market
7.3.6.1. Market Size and Forecast, By Drug Type
7.3.6.2. Market Size and Forecast, By Route Of Administration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. Germany Infantile Spasms Therapeutics Market
7.3.7.1. Market Size and Forecast, By Drug Type
7.3.7.2. Market Size and Forecast, By Route Of Administration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. Italy Infantile Spasms Therapeutics Market
7.3.8.1. Market Size and Forecast, By Drug Type
7.3.8.2. Market Size and Forecast, By Route Of Administration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Spain Infantile Spasms Therapeutics Market
7.3.9.1. Market Size and Forecast, By Drug Type
7.3.9.2. Market Size and Forecast, By Route Of Administration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. UK Infantile Spasms Therapeutics Market
7.3.10.1. Market Size and Forecast, By Drug Type
7.3.10.2. Market Size and Forecast, By Route Of Administration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Infantile Spasms Therapeutics Market
7.3.11.1. Market Size and Forecast, By Drug Type
7.3.11.2. Market Size and Forecast, By Route Of Administration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Drug Type
7.4.3. Market Size and Forecast, By Route Of Administration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. China Infantile Spasms Therapeutics Market
7.4.6.1. Market Size and Forecast, By Drug Type
7.4.6.2. Market Size and Forecast, By Route Of Administration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. Japan Infantile Spasms Therapeutics Market
7.4.7.1. Market Size and Forecast, By Drug Type
7.4.7.2. Market Size and Forecast, By Route Of Administration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Infantile Spasms Therapeutics Market
7.4.8.1. Market Size and Forecast, By Drug Type
7.4.8.2. Market Size and Forecast, By Route Of Administration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. South Korea Infantile Spasms Therapeutics Market
7.4.9.1. Market Size and Forecast, By Drug Type
7.4.9.2. Market Size and Forecast, By Route Of Administration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. Australia Infantile Spasms Therapeutics Market
7.4.10.1. Market Size and Forecast, By Drug Type
7.4.10.2. Market Size and Forecast, By Route Of Administration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Infantile Spasms Therapeutics Market
7.4.11.1. Market Size and Forecast, By Drug Type
7.4.11.2. Market Size and Forecast, By Route Of Administration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Drug Type
7.5.3. Market Size and Forecast, By Route Of Administration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Infantile Spasms Therapeutics Market
7.5.6.1. Market Size and Forecast, By Drug Type
7.5.6.2. Market Size and Forecast, By Route Of Administration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. South Africa Infantile Spasms Therapeutics Market
7.5.7.1. Market Size and Forecast, By Drug Type
7.5.7.2. Market Size and Forecast, By Route Of Administration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. Saudi Arabia Infantile Spasms Therapeutics Market
7.5.8.1. Market Size and Forecast, By Drug Type
7.5.8.2. Market Size and Forecast, By Route Of Administration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Infantile Spasms Therapeutics Market
7.5.9.1. Market Size and Forecast, By Drug Type
7.5.9.2. Market Size and Forecast, By Route Of Administration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Mallinckrodt Pharmaceuticals
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. H. Lundbeck A/S
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Pfizer Inc.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. UCB Pharma S.A.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Jazz Pharmaceuticals, Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Novartis AG
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Teva Pharmaceutical Industries Ltd.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Sun Pharmaceutical Industries Ltd.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Viatris Inc.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. AbbVie Inc.
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments